NYSEAMERICAN:CYBN Cybin (CYBN) Stock Price, News & Analysis $0.21 -0.01 (-4.54%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$0.21▼$0.2250-Day Range N/A52-Week Range$0.17▼$0.74Volume3.76 million shsAverage Volume4.91 million shsMarket Capitalization$86.36 millionP/E RatioN/ADividend YieldN/APrice Target$5.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartEarningsHeadlinesOwnershipShort InterestStock AnalysisAnalyst ForecastsChartEarningsHeadlinesOwnershipShort Interest Get Cybin alerts: Email Address Cybin MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside2,278.7% Upside$5.00 Price TargetShort InterestHealthy2.14% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.97Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.22) to ($0.10) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.20 out of 5 stars 3.5 Analyst's Opinion Consensus RatingCybin has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageCybin has received no research coverage in the past 90 days.Read more about Cybin's stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted2.14% of the float of Cybin has been sold short.Short Interest Ratio / Days to CoverCybin has a short interest ratio ("days to cover") of 3.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Cybin has recently increased by 16.95%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldCybin does not currently pay a dividend.Dividend GrowthCybin does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CYBN. Previous Next 2.8 News and Social Media Coverage News SentimentCybin has a news sentiment score of 0.97. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Cybin this week, compared to 0 articles on an average week.Search InterestOnly 12 people have searched for CYBN on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cybin insiders have not sold or bought any company stock.Percentage Held by Insiders15.00% of the stock of Cybin is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 17.94% of the stock of Cybin is held by institutions.Read more about Cybin's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Cybin are expected to grow in the coming year, from ($0.22) to ($0.10) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cybin is -1.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cybin is -1.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCybin has a P/B Ratio of 1.11. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsNASDAQ to crash 50%?During the 2020 Covid Crash he called a market reversal - eleven days before the S&P bottomed out... Now, he's saying there are four major cracks forming in the US economy...Click here to learn more >>> About Cybin Stock (NYSEAMERICAN:CYBN)Cybin Inc., a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in Phase 1/2a clinical trial to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine, which is in Phase 1 clinical trial for treating generalized anxiety disorders; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation. It has also developed EMBARK, a psychological support model that integrates clinical approaches to promote supportive healing with psychedelic medicine. The company is headquartered in Toronto, Canada.Read More CYBN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CYBN Stock News HeadlinesSeptember 1, 2024 | finance.yahoo.comCybin Inc. (CYBN.NE)August 28, 2024 | msn.comInvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Reports on Annual and Special Meeting of Shareholders, Share ConsolidationSeptember 7, 2024 | Behind the Markets (Ad)NASDAQ to crash 50%?During the 2020 Covid Crash he called a market reversal - eleven days before the S&P bottomed out... Now, he's saying there are four major cracks forming in the US economy...April 5, 2024 | theglobeandmail.comLSD, Ecstasy, magic mushrooms coming to a clinic near you? Legalization nears for psychedelicsApril 1, 2024 | msn.comInside George Soros’ Portfolio: His Top 8 Stock PicksApril 1, 2024 | msn.com10 Best Stocks To Buy Under $1March 31, 2024 | msn.comFan invades the pitch smoking marijuana and sniffing glue in BrazilMarch 30, 2024 | msn.comPsychedelics Headlines: A Form Of Life, Treating Chronic Pain, Microdosing And MoreSeptember 7, 2024 | Behind the Markets (Ad)NASDAQ to crash 50%?During the 2020 Covid Crash he called a market reversal - eleven days before the S&P bottomed out... Now, he's saying there are four major cracks forming in the US economy...March 20, 2024 | msn.comPsyched: LSD, Psilocybin As Breakthrough Therapies, $14M Fed Grant For Ibogaine, Indiana's Research And MoreMarch 15, 2024 | msn.comCybin initiates Phase 2 study for psychedelic drug DMTMarch 13, 2024 | msn.comFDA Grants Cybin Breakthrough Therapy Status For Major Depression Psilocybin Therapy, Company Announces Positive Clinical Data & Canadian $150M Private PlacementMarch 13, 2024 | msn.comCybin spikes after FDA breakthrough tag for psychedelic therapyMarch 13, 2024 | finance.yahoo.comAnnounces Oversubscribed Private Placement of U.S. $150 MillionFebruary 27, 2024 | finance.yahoo.comCybin to Present at the TD Cowen 44th Annual Health Care ConferenceFebruary 22, 2024 | benzinga.comCybin Stock (AMEX:CYBN) Earnings Dates and Earning CallsFebruary 17, 2024 | finance.yahoo.comALPN Mar 2024 25.000 callFebruary 16, 2024 | benzinga.comCybin Inc. Q3 Earnings: Clinical Advances Amid Financial LossSee More Headlines Receive CYBN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cybin and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/08/2024Today9/07/2024Fiscal Year End3/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSEAMERICAN SectorMedical Industry Biotechnology Sub-IndustryPharmaceutical Products Current SymbolNYSEAMERICAN:CYBN CUSIPN/A CIKN/A Webwww.cybin.com Phone908-764-8385FaxN/AEmployees50Year FoundedN/APrice Target and Rating Average Stock Price Target$5.00 High Stock Price Target$5.00 Low Stock Price Target$5.00 Potential Upside/Downside+2,278.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.21) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-35,930,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-109.05% Return on Assets-97.85% Debt Debt-to-Equity RatioN/A Current Ratio5.76 Quick Ratio5.76 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.19 per share Price / Book1.11Miscellaneous Outstanding Shares410,860,000Free Float349,227,000Market Cap$86.36 million OptionableNot Optionable Beta0.50 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesMr. Eric So L.L.B. (Age 48)Co-Founder, President & Executive Chairman Comp: $455.94kMr. Douglas L. Drysdale (Age 54)Chief Executive Officer Comp: $609.51kMr. Paul Glavine (Age 35)Co-Founder, Chief Growth Officer & Director Comp: $455.94kMr. Greg Cavers (Age 53)Chief Financial Officer Comp: $240.54kMr. Aaron BartloneChief Operating OfficerMr. John Kanakis (Age 44)Co-Founder Comp: $699.52kDr. Alex L. Nivorozhkin Ph.D. (Age 64)Chief Scientific Officer Ms. Lori ChallengerChief Compliance, Ethics & Administrative OfficerMr. Gabriel Fahel (Age 48)Chief Legal Officer & Corporate Secretary Sara Brittany SomersetChief Communications OfficersMore ExecutivesKey CompetitorsXeris BiopharmaNASDAQ:XERSFate TherapeuticsNASDAQ:FATEAquestive TherapeuticsNASDAQ:AQSTZevra TherapeuticsNASDAQ:ZVRAAura BiosciencesNASDAQ:AURAView All Competitors CYBN Stock Analysis - Frequently Asked Questions How have CYBN shares performed this year? Cybin's stock was trading at $0.4135 at the beginning of 2024. Since then, CYBN stock has decreased by 49.2% and is now trading at $0.2102. View the best growth stocks for 2024 here. How were Cybin's earnings last quarter? Cybin Inc. (NYSEAMERICAN:CYBN) released its quarterly earnings results on Thursday, August, 8th. The company reported ($0.01) earnings per share (EPS) for the quarter. How do I buy shares of Cybin? Shares of CYBN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSEAMERICAN:CYBN) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cybin Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cybin With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.